Structure-function relationships in a -galactosidase A

Acta Paediatrica, International Journal of Paediatrics

Volumn 96, Issue SUPPL. 455, 2007, Pages 6-16

  Garman, Scott C ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

Galactosidase; E.C. 3.2.1.22; Fabry disease; Glycosidase; Lysosomal storage disease

Indexed keywords

ALPHA GALACTOSIDASE; AMINO ACID;

CONFERENCE PAPER; CRYSTAL STRUCTURE; ENZYME ACTIVITY; ENZYME DEFECT; ENZYME POLYMORPHISM; ENZYME STRUCTURE; ENZYMOLOGY; FABRY DISEASE; GENE DELETION; GENE MUTATION; LYSOSOME STORAGE DISEASE; MISSENSE MUTATION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; STRUCTURE ACTIVITY RELATION;

ALPHA-GALACTOSIDASE; CRYSTALLOGRAPHY, X-RAY; DATABASES, GENETIC; EXONS; FABRY DISEASE; HUMANS; MUTATION; PROTEIN CONFORMATION; PROTEIN FOLDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33947592355     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2007.00198.x     Document Type: Conference Paper

References (86)

1. Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular bases of inherited disease. 8th ed. New York: McGraw-Hill, 2001: 3733-74.
2. Fabry J. Ein Beitrag zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae). Arch Dermatol Syph 1898; 43: 187-200.
3. Brady RO, Gal AE, Bradley RM, Martensson E, Warshaw AL, Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J Med 1967; 276: 1163-7.
4. Brady RO. Enzyme replacement therapy: conception, chaos and culmination. Philos Trans R Soc Lond B Biol Sci 2003; 358: 915-9.
5. Brady RO. Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies. Acta Paediatr Suppl 2003; 92: 19-24.
6. Garman SC, Garboczi DN. The molecular defect leading to Fabry disease: structure of human α-galactosidase. J Mol Biol 2004; 337: 319-35.
7. Bourne Y, Henrissat B. Glycoside hydrolases and glycosyltransferases: families and functional modules. Curr Opin Struct Biol 2001; 11: 593-600.
8. Lee K, Jin X, Zhang K, Copertino L, Andrews L, Baker-Malcolm J, et al. A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. Glycobiology 2003; 13: 305-13.
9. Ioannou YA, Zeidner KM, Gordon RE, Desnick RJ. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am J Hum Genet 2001; 68: 14-25.
10. McKusick VA. Mendelian inheritance in man: a catalog of human genes and genetic disorders. Baltimore: Johns Hopkins University Press, 1998.
11. Bairoch A, Apweiler R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res 2000; 28: 45-8.
12. Krawczak M, Cooper DN. The human gene mutation database. Trends Genet 1997; 13: 121-2.
13. Brünger AT, Adams PD, Clore GM, DeLano WL, Gros P, Grosse-Kunstleve RW, et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr 1998; 54: 905-21.
14. Kraulis PJ. MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J Appl Crystallogr 1991; 24: 946-50.
15. Shabbeer J, Yasuda M, Benson SD, Desnick RJ. Fabry disease: identification of 50 novel α-galactosidase A mutations causing the classic phenotype and three-dimensional structural analysis of 29 missense mutations. Hum Genomics 2006; 2: 297-309.
16. Matsuzawa F, Aikawa S, Doi H, Okumiya T, Sakuraba H. Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes. Hum Genet 2005; 117: 317-28.
17. Blanch LC, Meaney C, Morris CP. A sensitive mutation screening strategy for Fabry disease: detection of nine mutations in the alpha-galactosidase A gene. Hum Mutat 1996; 8: 38-43.
18. Eng CM, Ashley GA, Burgert TS, Enriquez AL, D'Souza M, Desnick RJ. Fabry disease: thirty-five mutations in the α-galactosidase A gene in patients with classic and variant phenotypes. Mol Med 1997; 3: 174-82.
19. Shabbeer J, Yasuda M, Luca E, Desnick RJ. Fabry disease: 45 novel mutations in the α-galactosidase A gene causing the classical phenotype. Mol Genet Metab 2002; 76: 23-30.
20. Tse KC, Chan KW, Tin VP, Yip PS, Tang S, Li FK, et al. Clinical features and genetic analysis of a Chinese kindred with Fabry's disease. Nephrol Dial Transplant 2003; 18: 182-6.
21. Garzuly F, Marodi L, Erdos M, Grubits J, Varga Z, Gelpi E, et al. Megadolichobasilar anomaly with thrombosis in a family with Fabry's disease and a novel mutation in the alpha-galactosidase A gene. Brain 2005; 128: 2078-83.
22. Teragaki M, Tanaka A, Akioka K, Lan HT, Nishi Y, Yamano T, et al. Fabry disease female proband with clinical manifestations similar to hypertrophic cardiomyopathy. Jpn Heart J 2004; 45: 685-9.
23. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995; 333: 288-93.
24. Madsen KM, Hasholt L, Sorensen SA, Fermer ML, Dahl N. Two novel mutations (L32P) and (G85N) among five different missense mutations in six Danish families with Fabry's disease. Hum Mutat 1995; 5: 277-8.
25. Eng CM, Resnick-Silverman LA, Niehaus DJ, Astrin KH, Desnick RJ. Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet 1993; 53: 1186-97.
26. Davies J, Christomanou H, Winchester B, Malcolm S. Detection of 8 new mutations in the alpha-galactosidase A gene in Fabry disease. Hum Mol Genet 1994; 3: 667-9.
27. Koide T, Ishiura M, Iwai K, Inoue M, Kaneda Y, Okada Y, et al. A case of Fabry's disease in a patient with no α-galactosidase A activity caused by a single amino acid substitution of Pro-40 by Ser. FEBS Lett 1990; 259: 353-6.
28. Ashton-Prolla P, Tong B, Shabbeer J, Astrin KH, Eng CM, Desnick RJ. Fabry disease: twenty-two novel mutations in the alpha-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 2000; 48: 227-35.
29. Davies JP, Eng CM, Hill JA, Malcolm S, MacDermot K, Winchester B, et al. Fabry disease: fourteen alpha-galactosidase A mutations in unrelated families from the United Kingdom and other European countries. Eur J Hum Genet 1996; 4: 219-24.
30. Rosenthal D, Lien YH, Lager D, Lai LW, Shang S, Leung N, et al. A novel alpha-galactosidase a mutant (M42L) identified in a renal variant of Fabry disease. Am J Kidney Dis 2004; 44: e85-9.
31. Iga MI, Okayama A, Matsuyama M, Sasaki T, Murai K, Hashida S, et al. Human gene mutations in GLA. Hum Genet 2001; 109: 126.
32. Germain DP, Shabbeer J, Cotigny S, Desnick RJ. Fabry disease: twenty novel α-galactosidase A mutations and genotype-phenotype correlations in classical and variant phenotypes. Mol Med 2002; 8: 306-12.
33. Sakuraba H, Oshima A, Fukuhara Y, Shimmoto M, Nagao Y, Bishop DF, et al. Identification of point mutations in the alpha-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 1990; 47: 784-9.
34. Wang ZX, Zhang Y, Bu DF, Zhang W, Yuan Y. Novel GLA gene mutations in two Chinese families with classic Fabry disease. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2005; 22: 489-92.
35. Blaydon D, Hill J, Winchester B. Fabry disease: 20 novel GLA mutations in 35 families. Hum Mutat 2001; 18: 459.
36. Cooper A, Cooper JA, Wraith JE. Human gene mutations in GLA. Hum Genet 2000; 107: 535-6.
37. Rodriguez-Mari A, Coll MJ, Chabas A. Molecular analysis in Fabry disease in Spain: fifteen novel GLA mutations and identification of a homozygous female. Hum Mutat 2003; 22: 258.
38. Ashley GA, Shabbeer J, Yasuda M, Eng CM, Desnick RJ. Fabry disease: twenty novel alpha-galactosidase A mutations causing the classical phenotype. J Hum Genet 2001; 46: 192-6.
39. Eng CM, Niehaus DJ, Enriquez AL, Burgert TS, Ludman MD, Desnick RJ. Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletional hot-spot in the α-galactosidase A gene. Hum Mol Genet 1994; 3: 1795-9.
40. Topaloglu AK, Ashley GA, Tong B, Shabbeer J, Astrin KH, Eng CM, et al. Twenty novel mutations in the α-galactosidase A gene causing Fabry disease. Mol Med 1999; 5: 806-11.
41. Shabbeer J, Robinson M, Desnick RJ. Detection of alpha-galactosidase a mutations causing Fabry disease by denaturing high performance liquid chromatography. Hum Mutat 2005; 25: 299-305.
42. Schäfer E, Baron K, Widmer U, Deegan P, Neumann HP, Sunder-Plassmann G, et al. Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease. Hum Mutat 2005; 25: 412.
43. Chen CH, Shyu PW, Wu SJ, Sheu SS, Desnick RJ, Hsiao KJ. Identification of a novel point mutation (S65T) in alpha-galactosidase A gene in Chinese patients with Fabry disease. Mutations in brief no. 169. Online. Hum Mutat 1998; 11: 328-30.
44. Lai LW, Whitehair O, Wu MJ, O'Meara M, Lien YH. Analysis of splice-site mutations of the α-galactosidase A gene in Fabry disease. Clin Genet 2003; 63: 476-82.
45. Ishii S, Sakuraba H, Suzuki Y. Point mutations in the upstream region of the alpha-galactosidase A gene exon 6 in an atypical variant of Fabry disease. Hum Genet 1992; 89: 29-32.
46. Okumiya T, Kawamura O, Itoh K, Kase R, Ishii S, Kamei S, et al. Novel missense mutation (M72V) of α-galactosidase gene and its expression product in an atypical Fabry hemizygote. Hum Mutat 1998; Suppl 1: S213-16.
47. Slee PH, van Boven LJ, Slee DS. Fabry disease: data from four families. Ned Tijdschr Geneeskd 2000; 144: 2412-15.
48. Guffon N, Froissart R, Chevalier-Porst F, Maire I. Mutation analysis in 11 French patients with Fabry disease. Hum Mutat 1998; Suppl 1: S288-90.
49. Takata T, Okumiya T, Hayashibe H, Shimmoto M, Kase R, Itoh K, et al. Screening and detection of gene mutations in Japanese patients with Fabry disease by non-radioactive single-stranded conformation polymorphism analysis. Brain Dev 1997; 19: 111-6.
50. Lee JK, Kim GH, Kim JS, Kim KK, Lee MC, Yoo HW. Identification of four novel mutations in five unrelated Korean families with Fabry disease. Clin Genet 2000; 58: 228-33.
51. Dobrovolny R, Dvorakova L, Ledvinova J, Magage S, Bultas J, Lubanda JC, et al. Relationship between X-inactivation and clinical involvement in Fabry heterozygotes. Eleven novel mutations in the alpha-galactosidase A gene in the Czech and Slovak population. J Mol Med 2005; 83: 647-54.
52. Kimura K, Sato-Matsumura KC, Nakamura H, Onodera Y, Morita K, Enami N, et al. A novel A97P amino acid substitution in alpha-galactosidase A leads to a classical Fabry disease with cardiac manifestations. Br J Dermatol 2002; 147: 545-8.
53. Kotanko P, Kramar R, Devrnja D, Paschke E, Voigtlander T, Auinger M, et al. Results of a nationwide screening for Anderson-Fabry disease among dialysis patients. J Am Soc Nephrol 2004; 15: 1323-9.
54. Whybra C, Kampmann C, Willers I, Davies J, Winchester B, Kriegsmann J, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24: 715-24.
55. Okumiya T, Ishii S, Kase R, Kamei S, Sakuraba H, Suzuki Y. α-Galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum Genet 1995; 95: 557-61.
56. Ploos van Amstel JK, Jansen RP, de Jong JG, Hamel BC, Wevers RA. Six novel mutations in the α-galactosidase A gene in families with Fabry disease. Hum Mol Genet 1994; 3: 503-5.
57. Eng CM, Desnick RJ. Molecular basis of Fabry disease: mutations and polymorphisms in the human α-galactosidase A gene. Hum Mutat 1994; 3: 103-11.
58. Germain D, Biasotto M, Tosi M, Meo T, Kahn A, Poenaru L. Fluorescence-assisted mismatch analysis (FAMA) for exhaustive screening of the α-galactosidase A gene and detection of carriers in Fabry disease. Hum Genet 1996; 98: 719-26.
59. Rosenberg KM, Schiffmann R, Kaneski C, Brady RO, Sorensen SA, Hasholt L. Five novel mutations in fourteen patients with Fabry disease. Hum Mutat 2000; 15: 207-8.
60. Morrone A, Cavicchi C, Bardelli T, Antuzzi D, Parini R, Di Rocco M, et al. Fabry disease: molecular studies in Italian patients and X inactivation analysis in manifesting carriers. J Med Genet 2003; 40: e103.
61. Yasuda M, Shabbeer J, Benson SD, Desnick RJ. Fabry disease: identification/characterization of novel double mutations in the α-galactosidase A gene. ASHG Annual Meeting Abstracts 2002; 926.
62. Ries M, Gupta S, Moore DF, Sachdev V, Quirk JM, Murray GJ, et al. Pediatric Fabry disease. Pediatrics 2005; 115: e344-55.
63. Davies JP, Winchester BG, Malcolm S. Mutation analysis in patients with the typical form of Anderson-Fabry disease. Hum Mol Genet 1993; 2: 1051-3.
64. Meaney C, Blanch LC, Morris CP. A nonsense mutation (R220X) in the alpha-galactosidase A gene detected in a female carrier of Fabry disease. Hum Mol Genet 1994; 3: 1019-20.
65. Yang CC, Lai LW, Whitehair O, Hwu WL, Chiang SC, Lien YH. Two novel mutations in the α-galactosidase A gene in Chinese patients with Fabry disease. Clin Genet 2003; 63: 205-9.
66. Germain DP, Poenaru L. Fabry disease: identification of novel α-galactosidase A mutations and molecular carrier detection by use of fluorescent chemical cleavage of mismatches. Biochem Biophys Res Commun 1999; 257: 708-13.
67. Knol IE, Ausems MG, Lindhout D, van Diggelen OP, Verwey H, Davies J, et al. Different phenotypic expression in relatives with Fabry disease caused by a W226X mutation. Am J Med Genet 1999; 82: 436-9.
68. Redonnet-Vernhet I, Ploos van Amstel JK, Jansen RP, Wevers RA, Salvayre R, Levade T. Uneven X inactivation in a female monozygotic twin pair with Fabry disease and discordant expression of a novel mutation in the α-galactosidase A gene. J Med Genet 1996; 33: 682-8.
69. Altarescu GM, Goldfarb LG, Park KY, Kaneski C, Jeffries N, Litvak S, et al. Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001; 60: 46-51.
70. Okumiya T, Ishii S, Takenaka T, Kase R, Kamei S, Sakuraba H, et al. Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem Biophys Res Commun 1995; 214: 1219-24.
71. Azibi K, Caillaud C, Manicom J, Puech JP, Kahn A, Poenaru L. Fabry disease: identification of ten novel mutations. ASHG Annual Meeting Abstracts 2001; 2647.
72. Verovnik F, Benko D, Vujkovac B, Linthorst GE. Remarkable variability in renal disease in a large Slovenian family with Fabry disease. Eur J Hum Genet 2004; 12: 678-81.
73. Dominissini S, Cariati R, Nevyjel M, Guerci V, Ciana G, Bembi B, et al. Comparative in vitro expression study of four Fabry disease causing mutations at glutamine 279 of the alpha-galactosidase A protein. Hum Hered 2004; 57: 138-41.
74. von Scheidt W, Eng CM, Fitzmaurice TF, Erdmann E, Hubner G, Olsen EG, et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991; 324: 395-9.
75. Yasuda M, Shabbeer J, Benson SD, Maire I, Burnett RM, Desnick RJ. Fabry disease: characterization of alpha-galactosidase A double mutations and the D313Y plasma enzyme pseudodeficiency allele. Hum Mutat 2003; 22: 486-92.
76. Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ, et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002; 105: 1407-11.
77. Beyer E, Djatlovitskaya E, Zairatyants O, Berestova A, Mendelson M, Brook E, et al. Identification of Fabry disease in two brothers. J Inherit Metab Dis 1990; 13: 230-1.
78. Azibi K, Caillaud C, Heltianu C, Dussau J, Poenaru L. Novel mutations and genetic markers of Fabry disease. ASHG Annual Meeting Abstracts 2002; 2170.
79. Bernstein HS, Bishop DF, Astrin KH, Kornreich R, Eng CM, Sakuraba H, et al. Fabry disease: six gene rearrangements and an exonic point mutation in the α-galactosidase gene. J Clin Invest 1989; 83: 1390-9.
80. Miyazaki T, Kajita M, Ohmori S, Mizutani N, Niwa T, Murata Y, et al. A novel mutation (E358K) in the α-galactosidase A gene detected in a Japanese family with Fabry disease. Hum Mutat 1998; Suppl 1: S139-40.
81. Miyamura N, Araki E, Matsuda K, Yoshimura R, Furukawa N, Tsuruzoe K, et al. A carboxy-terminal truncation of human alpha-galactosidase A in a heterozygous female with Fabry disease and modification of the enzymatic activity by the carboxy-terminal domain. Increased, reduced, or absent enzyme activity depending on number of amino acid residues deleted. J Clin Invest 1996; 98: 1809-17.
82. Germain DP, Salard D, Fellmann F, Azibi K, Caillaud C, Bernard MC, et al. Identification of a novel de novo mutation (G373D) in the α-galactosidase A gene (GLA) in a patient affected with Fabry disease. Hum Mutat 2001; 17: 353.
83. Shin YS, Podskarbi T. A novel mutation of the α-galactosidase A gene in a family with juvenile-onset form of Fabry disease. ASHG Annual Meeting Abstracts 2001; 1799.
84. Galanos J, Nicholls K, Grigg L, Kiers L, Crawford A, Becker G. Clinical features of Fabry's disease in Australian patients. Intern Med J 2002; 32: 575-84.
85. Cariolou MA, Christodoulides M, Manoli P, Kokkofitou A, Tsambaos D. Novel trinucleotide deletion in Fabry's disease. Hum Genet 1996; 97: 468-70.
86. Novo FJ, Kruszewski A, MacDermot KD, Goldspink G, Gorecki DC. Editing of human α-galactosidase RNA resulting in a pyrimidine to purine conversion. Nucleic Acids Res 1995; 23: 2636-40.